Belantamab mafodotin is under clinical development by GSK and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Belantamab mafodotin’s likelihood of approval (LoA) and phase transition for Diffuse Large B-Cell Lymphoma took place on 28 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
In addition, the same event on 28 Nov 2022 decreased Belantamab mafodotin’s LoA and PTSR for Follicular Lymphoma.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Belantamab mafodotin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Belantamab mafodotin overview
Belantamab mafodotin (Blenrep) is a B-cell maturation antigen (BCMA)-directed antibody is produced in a mammalian cell line (Chinese Hamster Ovary) using recombinant DNA technology. It is formulated as lyophilized powder for solution for intravenous route of administered. Blenrep is indicated for the treatment multiple myeloma of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
The drug candidate is under development for the treatment of relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma, relapsed or refractory AL amyloidosis, relapsed or refractory AL amyloidosis, relapsed or refractory multiple myeloma, diffuse large B-Cell lymphoma and follicular lymphoma
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
Quick View Belantamab mafodotin LOA Data
|Highest Development Stage|